1. Inicio
  2. Publicaciones
  3. Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study.

Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Melgosa Ramos FJ
  • Alarcón SS
  • Puchades AM
  • Romero IB
  • Pastor GMP
  • Apetrei LS
  • Díaz FJM
  • Martorell A
  • Pastor MV
  • Salvador JMO
  • Galarreta Pascual M
  • Magdaleno Tapial J

Grupos

Abstract

Managing moderate-to-severe psoriasis in patients with current or past malignancy remains a therapeutic challenge. We conducted a multicentre, retrospective real-world study to assess the safety and effectiveness of guselkumab in this complex population. Thirty patients were included, of whom 11 had active cancer at the time of guselkumab initiation. After 52 weeks of follow-up, guselkumab achieved sustained clinical improvement in skin and joint symptoms, with no observed cases of cancer progression or recurrence. Two patients developed new malignancies during treatment, but guselkumab was not discontinued. These findings support the use of IL-23 inhibitors as a safe therapeutic option in this complex patient population.

© 2025 Australasian College of Dermatologists.

Datos de la publicación

ISSN/ISSNe:
0004-8380, 1440-0960

AUSTRALASIAN JOURNAL OF DERMATOLOGY  WILEY

Tipo:
Article
Páginas:
359-363
PubMed:
40923243
Factor de Impacto:
0,639 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • cancer; guselkumab; malignancy; psoriasis

Cita

Compartir